Compare Summit Therapeutics Inc (SMMT) vs Smurfit WestRock plc Ordinary Shares (SW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Smurfit WestRock plc Ordinary Shares — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Smurfit WestRock plc Ordinary Shares trades at $41.29 (market cap $21.74B). The key difference: Smurfit WestRock plc Ordinary Shares is the larger of the two by market cap, and Smurfit WestRock plc Ordinary Shares pays a 4.36% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Smurfit WestRock plc Ordinary Shares for 0 Days on average.
| SMMT | SW | |
|---|---|---|
Market Cap | $13.71B | $21.74B |
Volume | 6,173,057 | 5,178,763 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $51.84 |
52-Week Low | $12.43 | $32.79 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $13.04B | $35.23B |
Dividend Yield | — | 4.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →
